Drugs / HRS9432
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06194201 | Apr 2024 → Nov 2025 | candidiasis | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS9432 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194201 ↗ |
| Route | Intravenous | “Dosing frequency: intravenously once week” NCT06194201 ↗ |